Viking Therapeutics, Inc.

Viking Therapeutics, Inc. (NASDAQ: VK) is a clinical-stage biopharmaceutical company focused on developing novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. The company's website is www.vikingtherapeutics.com.

Viking's primary development focus centers on VK2735, a dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors being developed in both oral and subcutaneous formulations for metabolic disorders including obesity. The subcutaneous formulation completed a Phase 2 trial demonstrating statistically significant body weight reductions up to 14.7 percent from baseline, with the company advancing two Phase 3 studies, VANQUISH-1 and VANQUISH-2, which completed enrollment in late 2025. The oral formulation completed a Phase 2 trial in 2025 showing weight reductions up to 12.2 percent, with Phase 3 oral studies expected to initiate in the third quarter of 2026. Viking also initiated an exploratory Phase 1 maintenance dosing study to evaluate various dosing regimens for sustaining weight loss.

Beyond VK2735, Viking is developing VK2809, an orally available selective thyroid hormone receptor beta agonist for non-alcoholic steatohepatitis and metabolic liver disease. The Phase 2b VOYAGE study demonstrated that up to 75 percent of VK2809-treated patients achieved disease resolution with no worsening of fibrosis, compared to 29 percent for placebo. The company is also advancing VK0214, another selective thyroid receptor beta agonist, for X-linked adrenoleukodystrophy, a rare neurological disorder. A Phase 1b trial showed VK0214 was safe and well-tolerated with significant reductions in very long chain fatty acid levels.

Viking maintains a preclinical dual amylin and calcitonin receptor agonist program targeting obesity, with an investigational new drug application planned for the first quarter of 2026. The company also holds VK5211, a selective androgen receptor modulator for hip fracture recovery, though it is pursuing partnering opportunities for this program.

In March 2025, Viking secured broad manufacturing agreements with CordenPharma covering active pharmaceutical ingredient and finished product supply for VK2735, with dedicated capacity for multiple metric tons of API and over one billion annual oral tablets.